The Senate Appropriations Committee has released its FY27 spending bills, reflecting several important priorities PPMD and our advocates have worked to advance on behalf of the Duchenne and Becker community.
The bills include provisions supporting Duchenne and Becker research, improved disease surveillance, and expanded newborn screening. While the appropriations process is not yet complete, these developments represent meaningful progress toward addressing the needs of individuals and families across every stage of the Duchenne and Becker journey.
Key priorities reflected in the Senate bills include:
- CDC research and disease surveillance: A $1 million increase for muscular dystrophy research and surveillance initiatives, with report language encouraging continued work to better understand Duchenne and Becker outcomes across the lifespan, including bone health, cardiovascular and cognitive function, adult care, and the experiences of individuals receiving multiple therapies.
- Department of Defense research funding: $12.5 million for peer-reviewed Duchenne muscular dystrophy research, maintaining the funding level from FY26.
- NIH research and next-generation therapies: Report language encouraging the National Institutes of Health (NIH) to develop a coordinated, multi-Institute strategy to accelerate DNA- and RNA-directed platform technologies, with particular attention to rare and challenging genotypes that may be underserved by current therapeutic development approaches. A $500 million proposed increase to overall NIH funding is also included.
- Newborn screening: Support for states implementing Duchenne and metachromatic leukodystrophy newborn screening, following the addition of both conditions to the Recommended Uniform Screening Panel (RUSP) in December 2025. The bill also directs the Health Resources and Services Administration (HRSA) to report on how additional funding will be distributed to states and how implementation of these conditions will be prioritized.
The Work Ahead
These provisions reflect important progress and the impact of sustained advocacy by individuals and families, congressional champions, and partners working to advance the Duchenne and Becker community’s priorities.
However, the Senate committee’s release of these bills is one step in the federal appropriations process. The provisions must continue through the legislative process before funding and directives can be finalized.
PPMD urges Congress to build on this progress, advance these priorities, and complete the FY27 appropriations process. Continued investment in research, care, and newborn screening is essential to improving outcomes and expanding opportunities for everyone living with Duchenne and Becker.
Thank you to the advocates, partners, and congressional leaders who continue to make these priorities heard. Together, we are moving progress forward.
Take Action Today
The Senate Appropriations Committee has released its FY27 spending bills, reflecting several important priorities that PPMD and our advocates have worked hard to advance, including investments in Duchenne and Becker research, disease surveillance, next-generation therapies, and newborn screening.
Now, we need your help ensuring these priorities are reflected in the House of Representatives’ FY27 appropriations legislation.
The post Senate Appropriations Bills Advance Priorities for the Duchenne and Becker Community appeared first on Parent Project Muscular Dystrophy.
